Video

Incorporating Precision Medicine into Oncology

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

Terrill Jordan, LLM, JD, president and chief executive officer, Regional Cancer Care Associates, discusses challenges regarding the utility of precision medicine in oncology.

There is a robust pipeline of drugs in development in oncology, explains Jordan. The number of agents that are poised to enter the market may complicate current treatment strategies.

Notably, precision medicine has helped individualize treatment for patients. Among the flood of new agents, physicians should consider patient-specific factors when choosing a treatment.

Precision medicine can be costly; however, it appears to be cost-effective in the long-term, concludes Jordan.

Related Videos
Martin Dreyling, MD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers
David Samuel Dicapua Siegel, MD
Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Andrew Ip, MD
Yousef Zakharia, MD
Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.
Mansi R. Shah, MD